Tonix Pharmaceuticals reported Q2 2026 net revenue of $13.5M, driven by Tanmya's $11M sales. Prescription growth soared 100% QoQ. R&D expenses rose sharply.
Tonix Pharmaceuticals Holding Corp. reported Q2 2026 net product revenue of approximately $13.5 million, significantly up from $2 million in the same period last year and exceeding analyst expectations. The substantial growth was driven primarily by the successful launch of Tanmya, which achieved net sales of $11 million, marking a 197% increase quarter over quarter.
Key Takeaways
- Tanmay Sales reached $11 million in Q2 2026, a 197% increase from Q1 2026.
- Prescription Growth for Tanmya saw a 100% quarter-over-quarter increase, totaling 12,592 prescriptions.
- Gross Margin on Tanmya improved significantly with cost of sales at approximately $0.7 million, down from $3.3 million year-over-year.
- R&D Expenses rose to $19.4 million, compared to $10.8 million in Q2 2025, primarily due to increased clinical trial activities.
- Cash Position as of June 30, 2026, stood at approximately $176.2 million, down from $207.6 million at the end of 2025.
Tanmya Launch Drives Revenue Growth
Tonix's revenue surge can be attributed to the strong market entry of Tanmya, an innovative treatment for fibromyalgia. In the second quarter, Tanmya's sales hit $11 million, nearly tripling from the previous quarter. This performance reflects a solid adoption among healthcare providers and patients alike.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Net Product Revenue | $13.5M | +575% | +101% |
| Tanmya Sales | $11M | N/A | +197% |
| Total Prescriptions | 12,592 | N/A | +100% |
| R&D Expenses | $19.4M | +80% | N/A |
| Cash Position | $176.2M | N/A | -14% |
In addition to the revenue increases, Tonix reported a significant uptick in prescription metrics: new patient starts rose 36%, while refills soared by 207%. Management is optimistic that the continued rollout of Tanmya will sustain this growth trajectory as the company expands its sales force by 50 representatives in September 2026, targeting major healthcare providers.
Clinical Pipeline Progress
Tonix is also advancing its clinical pipeline, with the TNX102SL program targeting major depressive disorder (MDD) showing promise. The company reported the randomization of its first patient in a pivotal Phase 2 study for TNX102SL, which aims to enroll approximately 360 patients. The study will evaluate the drug's efficacy as a first-line treatment in adults suffering from MDD.
In parallel, the TNX4800 program, aimed at preventing Lyme disease, is preparing for its Phase 2 study, expected to begin enrollment in early 2027. The company has received positive feedback from the FDA regarding its study design, which could position TNX4800 as a potential game-changer in Lyme disease prevention.
Increased Operational Investments
The financial results reflect Tonix's commitment to enhancing its operational capabilities, particularly in the area of research and development. R&D expenditures rose to $19.4 million in Q2, primarily due to costs associated with clinical trials for its pipeline candidates. The increase in selling, general, and administrative expenses to $36 million was largely driven by investments in marketing and sales strategies for Tanmya.
Despite increased spending, the company ended the quarter with $176.2 million in cash and cash equivalents, providing a solid financial foundation to support its ongoing clinical and commercial initiatives.
Analyst Q&A Highlights
During the analyst Q&A, management was pressed on the sustainability of the Tanmya launch momentum and the anticipated gross-to-net changes moving forward. Management indicated that while fluctuations are expected as coverage agreements come online, they maintain a favorable outlook on ongoing sales growth.
“We expect continued fluctuations for gross to net in both Q3 and Q4,” noted Tom Inglese, EVP of Commercial Operations, emphasizing the importance of securing market access agreements in driving patient uptake.
Analysts also queried about the upcoming TNX4800 study, with Tonix addressing concerns regarding infection rates and patient recruitment strategies. The company believes that the current rise in Lyme disease cases in the U.S. will facilitate adequate enrollment and provide sufficient data for potential efficacy.
Frequently Asked Questions
Did Tonix Pharmaceuticals Holding Corp. beat earnings estimates in Q2 2026?
Yes, Tonix reported net product revenue of approximately $13.5 million, exceeding consensus estimates.
How many prescriptions were filled for Tanmya in Q2 2026?
Tanmay prescriptions totaled 12,592 in Q2 2026, representing a 100% increase over Q1 2026.
What are the upcoming milestones for TNX102SL?
The TNX102SL program is set to begin patient enrollment in a pivotal Phase 2 study targeting major depressive disorder in early 2027.
How much cash did Tonix have at the end of Q2 2026?
As of June 30, 2026, Tonix had approximately $176.2 million in cash and cash equivalents.
What are the expected implications of the TNX4800 study?
The TNX4800 study aims to provide pivotal evidence for Lyme disease prevention, with enrollment expected to begin in 2027.
Tonix Pharmaceuticals' strong sales growth from Tanmya and advancements in clinical programs set the stage for potential strategic growth moving forward, but execution in the upcoming quarters will be crucial to maintain investor confidence and market momentum.
This analysis is based on public earnings call materials and is not investment advice.
